Evidence map›Paper›PMID 41496551›Full record

ArticleOncoimmunology2026

Oncolytic virus OVV-03 enhances CAR-T cell therapy against glioblastoma via immune modulation and specific HER2 upregulation.

Yi Tang, Qinzhi E, Liang Ma, Xuetao Li, Yang Zhang, Weichao Wang, Zuoyu Jiang, Xuewen Zhang, Yingbo Hou, Jiaming Du and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Yi TangDepartment of Neurosurgery, The Fourth Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.ORCID 0009-0000-5251-2583
Qinzhi EDepartment of Neurosurgery, The Fourth Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
Liang MaJoint Biosciences (SH) Ltd, Pudong New Area, Shanghai, People's Republic of China.
Xuetao LiDepartment of Neurosurgery, The Fourth Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
Yang ZhangDepartment of Neurosurgery, The Fourth Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
Weichao WangDepartment of Neurosurgery, The Fourth Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
Zuoyu JiangDepartment of Neurosurgery, The Fourth Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
Xuewen ZhangDepartment of Neurosurgery, The Fourth Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
Yingbo HouDepartment of Neurosurgery, The Fourth Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
Jiaming DuDepartment of Neurosurgery, The Fourth Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
Yang ZhuDepartment of Neurosurgery, The Fourth Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
Hanmiao DongDepartment of Neurosurgery, The Fourth Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
Yeyang XuDepartment of Neurosurgery, The Fourth Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
Ting TianJoint Biosciences (SH) Ltd, Pudong New Area, Shanghai, People's Republic of China.
Longxin ChengJoint Biosciences (SH) Ltd, Pudong New Area, Shanghai, People's Republic of China.
Qibin MaJoint Biosciences (SH) Ltd, Pudong New Area, Shanghai, People's Republic of China.
Jian LiDepartment of Neurosurgery, The Fourth Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.ORCID 0000-0001-9996-6021
Guoqing ZhouJoint Biosciences (SH) Ltd, Pudong New Area, Shanghai, People's Republic of China.ORCID 0009-0006-0059-8403
Yulun HuangDepartment of Neurosurgery, The Fourth Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.ORCID 0000-0002-5297-6967

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma (GBM) remains therapeutically challenging due to treatment resistance and immunosuppression. Oncolytic virotherapy offers a promising strategy. This study engineered OVV-03, a novel HER2-armed oncolytic vesicular stomatitis virus (VSV), and evaluated its efficacy against GBM. OVV-03 demonstrated potent infectivity and cytotoxicity in GBM cell lines and patient-derived cells, inducing caspase-dependent apoptosis and suppressing proliferation/clonogenicity. In murine GBM models, OVV-03 significantly suppressed tumor growth, improved survival, and enhanced CD8⁺ T cell infiltration. Single-cell RNA sequencing revealed OVV-03 remodels the tumor immune microenvironment by boosting cytotoxic T cell activity and inhibiting immunosuppressive pathways, notably PD-L1/PD-1 signaling. Mechanistically, OVV-03 downregulated PD-L1 by inhibiting the JNK-c-Fos/c-Jun axis, reversible by TNF-

Indexed as

Brain NeoplasmsErb-b2 Receptor Tyrosine KinasesGlioblastomaImmunotherapy, AdoptiveOncolytic VirotherapyOncolytic VirusesReceptors, Chimeric AntigenAnimalsCell Line, TumorFemaleHumansImmunomodulationMiceTumor MicroenvironmentUp-RegulationXenograft Model Antitumor AssaysERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, Chimeric AntigenCAR-T cellcombination therapyGBMoncolytic virustumor microenvironment

Identifiers

PMID41496551
PMCPMC12785206

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.